Hypomagnesaemia and its management following treatment with anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs): results from 3 randomized studies of necitumumab (NECI) plus chemotherapy in first-line treatment of patients with stage IV non-small cell lung cancer (NSCLC).
Authors
Vokes, ESocinski, M
Spigel, D
Paz-Ares, L
Kurek, R
Nanda, S
Grau, G
Shahidi, J
Thatcher, Nick
Gandara, D
Affiliation
Dept. of Medicine, The University of Chicago Medical Centre, ChicagoIssue Date
2016-10-01
Metadata
Show full item recordCitation
Hypomagnesaemia and its management following treatment with anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs): results from 3 randomized studies of necitumumab (NECI) plus chemotherapy in first-line treatment of patients with stage IV non-small cell lung cancer (NSCLC). 2016, 27(suppl_6):1256P Annals of OncologyJournal
Annals of OncologyDOI
10.1093/annonc/mdw383.56Additional Links
https://academic.oup.com/annonc/article/2800149/HypomagnesaemiaType
Meetings and ProceedingsLanguage
enISSN
0923-75341569-8041
ae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdw383.56